...
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Intradermal sufentanil does not improve lidocaine-induced local anesthesia.
【24h】

Intradermal sufentanil does not improve lidocaine-induced local anesthesia.

机译:皮内舒芬太尼不能改善利多卡因诱导的局部麻醉。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Peripheral opioid receptors may result in antinociceptive effects when occupied by opioids. This study examined intradermally injected sufentanil (S), a highly lipid soluble opioid, administered with and without lidocaine (L), in a thermal pain model. METHODS: Nine volunteers were instructed on the method of magnitude estimation of pain before undergoing baseline testing with seven seconds thermal stimuli between 44 and 52 degrees C, delivered by a contact thermal stimulator at five cutaneous forearm sites. Then, four sites randomly received injections of equal volumes (0.1 mL) of either normal saline (NS), lidocaine 0.5% (L), sufentanil 0.75 microg (S), lidocaine 0.5% plus sufentanil 0.75 microg (L+S), and one site was not injected and served as reference (REF). Testing was repeated at six, 30, 60, 90, 120, and 150 min following injection. The pain elicited by each stimulus was normalized to the subject's response to the 50 degrees C stimulus at the REF site. RESULTS: Baseline testing showed small (P = ns) differences in pain scores. At six minutes, the lidocaine sites (L, L+S) had pain scores that were mean 83% (range 78-88%) lower than the other sites (P < 0.05), but there was no difference between the L and L+S sites or between the S and NS or REF sites. At 30 and 60 min these pain scores were mean 38% (29-44%) and 20% (8-30%) less than at the REF, NS, and S sites (P = ns). At 90 min and later times, the pain scores had returned to baseline. CONCLUSIONS: These results suggest that intradermal sufentanil alone has no analgesic effect. Further, in combination with lidocaine, sufentanil does neither potentiate nor prolong the analgesic effect of lidocaine.
机译:目的:当被阿片类药物占据时,周围的阿片类药物受体可能会产生抗伤害感受的作用。这项研究检查了在热痛模型中皮内注射舒芬太尼(S),一种高度脂溶性阿片类药物,有或没有利多卡因(L)的情况。方法:在进行基线测试之前,对9名志愿者进行了疼痛程度的估算方法,该测试采用接触热刺激器在五个前臂皮肤部位进行的,在44至52摄氏度之间的7秒热刺激进行基线测试。然后,四个地点随机接受等体积(0.1 mL)的生理盐水(NS),利多卡因0.5%(L),舒芬太尼0.75微克(S),利多卡因0.5%加舒芬太尼0.75微克(L + S)和一个部位未注入,用作参考(REF)。注射后6、30、60、90、120和150分钟重复测试。每种刺激引起的疼痛均根据受试者对REF部位50摄氏度刺激的反应进行标准化。结果:基线测试显示疼痛评分的差异很小(P = ns)。在六分钟时,利多卡因部位(L,L + S)的疼痛评分平均比其他部位低83%(范围78-88%)(P <0.05),但L和L之间没有差异+ S站点或S与NS或REF站点之间。在30分钟和60分钟时,这些疼痛评分比REF,NS和S部位平均低38%(29-44%)和20%(8-30%)(P = ns)。在90分钟及以后的时间,疼痛评分已恢复到基线。结论:这些结果表明单独的皮内舒芬太尼没有镇痛作用。此外,与利多卡因合用时,舒芬太尼既不增强也不延长利多卡因的镇痛作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号